Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2023 | TROPION-PanTumor03: datopotamab deruxtecan in advanced solid tumors

Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides an overview of the Phase II TROPION-PanTumor03 trial (NCT05489211) of datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate (ADC) in patients with solid tumors. Cohorts include patients with gastric and colorectal cancer, where a number of patients have TROP2-positive tumors. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.